Abstract
OBJECTIVES Disulfiram, a low-cost generic drug used for alcohol dependence, holds the potential to mitigate disease progression in patients with moderate COVID-19 by targeting inflammasomes. This study aimed to evaluate the clinical efficacy and safety of disulfiram when administered alongside standard of care for the treatment of hospitalized individuals with moderate COVID-19.
DESIGN A randomized, double-blind, placebo-controlled trial.
SETTING Conducted at four clinical sites in Brazil between December 2020 and August 2021.
PARTICIPANTS 140 participants aged 35 and older with laboratory-confirmed SARS-CoV-2 infection, hospitalized for ≤5 days with moderate symptoms of COVID-19 were enrolled, 137 were randomized.
INTERVENTION Participants were randomized in a 1:1 ratio to receive a daily dose of 500 mg of disulfiram (N=68) or placebo (N=69) for 14 days while receiving the current standard of care. Randomization was stratified by age and comorbidities (hypertension, diabetes, and BMI ≥35).
MEASUREMENTS AND MAIN RESULTS The primary outcome, median time to clinical improvement [95% CI] did not significantly differ between groups (disulfiram: 3.5 [3.00, 4.00] days; placebo: 4 [3.00, 5.00] days; P=.73).
Key secondary outcomes, such as mean days (SD) on supplemental oxygen [disulfiram: 4.4 (6.61) days; placebo: 3.7 (5.80) days, P=.34], median (95% CI) time to hospital discharge [disulfiram: 6.0 (5.00, 8.00) days, placebo: 5.0 (4.00, 7.00)], proportion of participants discharged by day 8 [disulfiram (68%), placebo (63%), odds ratio: 0.801], and proportion of participants who clinically worsened [disulfiram (21%), placebo (19%), P=.79], did not reveal significant differences. While the incidence of adverse events was higher in the disulfiram group, serious adverse events and 28-day mortality were comparable between the two groups.
Conclusions Although disulfiram was found to be safe in hospitalized patients with moderate COVID-19, it did not shorten the time to clinical improvement. These findings do not support the use of disulfiram alongside standard of care in this patient population.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04594343
Background Disulfiram has been proposed to mitigate disease progression in patients with COVID-19 by targeting the inflammasomes.
Question Does disulfiram, a generic drug used for alcohol use disorder, reduce the time to clinical improvement or reduce the risk of severe disease in hospitalized patients with moderate COVID-19 and with comorbidities when added to the standard of care?
Findings In this double-blind, placebo-controlled randomized clinical trial of adults hospitalized with moderate COVID-19 in Brazil, the addition of an oral disulfiram treatment to the standard of care was safe. Still, it did not decrease the time to clinical improvement.
Meaning The study findings do not support the use of disulfiram in hospitalized patients with moderate COVID-19 in addition to the standard of care.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04594343
Funding Statement
The Spring Research Foundation, a non-profit organization, provided financial support for this clinical trial through generous donations
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study entitled "A Randomized, Double-Blind, Placebo-Controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19" received approval from the National Research Ethics Committee (Comissão Nacional de Ética em Pesquisa (CONEP), approval number: 4.408.019 on 11/18/2020) and from local Research Ethics Committees (Comitês de Ética em Pesquisa (CEP)): Ensino e Terapia de Inovacao Clinica AMO (ETICA), approval number: 4.280.370 on 09/16/2020; Hospital Bahia, approval number: 4.472.182 on 12/17/2020; Hospital Portugues, approval number: 4.592.906 on 03/16/2021.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
email address: augustomota{at}clinicaamo.com.br, valdir_cerq{at}yahoo.com.br, carolyn.hendrickson{at}ucsf.edu, rachel{at}springdisc.com, matt.donne{at}gmail.com, an{at}springdisc.com, caroline.junqueira{at}fiocruz.br, mark.marino{at}mtmarino.com, munish.mehra{at}tigermedgrp.com, 777rms{at}gmail.com, christian.elabd{at}gmail.com, kamens{at}springdisc.com, wendy.cousin{at}gmail.com
Financial support: Spring Research Foundation, a non-profit organization have funded the clinical trial.
Potential Conflicts of Interest: The authors have no conflicts of interest to disclose.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- AEs
- adverse events
- ARDS
- acute respiratory distress syndrome
- BMI
- body mass index
- cf-DNA
- cell-free DNA
- CONSORT
- consolidated standards of reporting trials
- DAIDS
- division of AIDS
- DSMB
- data and safety monitoring board
- GSDMD
- gasdermin D
- ICF
- informed consent form
- ICU
- intensive care unit
- IL
- interleukin
- LDH
- lactate dehydrogenase
- LS
- least square
- mITT
- modified intention-to-treat
- NETosis
- neutrophil extracellular traps formation
- +NLR
- neutrophil-to-lymphocyte ratio
- SAEs
- serious adverse events
- SAP
- statistical analysis plan
- SE
- standard error
- TNF
- tumor necrosis factor alpha
- WHO
- World Health Organization
